» Articles » PMID: 25104789

Diabetes Mellitus and Liver Cancer Risk: an Evaluation Based on a Systematic Review of Epidemiologic Evidence Among the Japanese Population

Overview
Specialty Oncology
Date 2014 Aug 9
PMID 25104789
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The potential associations of diabetes mellitus with malignant neoplasms including liver cancer have become a great concern from both clinical and preventive perspectives. Although sufficient evidence for a positive association between diabetes and liver cancer already exists, it would be informative to summarize up-to-date epidemiologic data in Japan.

Methods: We systematically reviewed epidemiologic studies on diabetes and liver cancer among Japanese populations. Original data were obtained by searching the MEDLINE (PubMed) and Ichushi databases, complemented with manual searches. The evaluation was performed in terms of the magnitude of association in each study and the strength of evidence ('convincing', 'probable', 'possible' or 'insufficient'), together with biological plausibility.

Results: We identified 19 cohort studies, one pooled-analysis of seven cohort studies, and seven case-control studies. Of 24 relative risk estimates of liver cancer for diabetes reported in those cohort studies, 17 showed a weak to strong positive association, six revealed no association and one demonstrated a weak inverse association (summary relative risk 2.10, 95% confidence interval 1.60-2.76). Ten relative risk estimates from the case-control studies showed a weak to strong positive association (n = 9) or no association (n = 1; summary relative risk 2.32, confidence interval 1.73-3.12). Overall, the summary relative risk became 2.18 (confidence interval 1.78-2.69). Heterogeneity in relative risks was significant for the difference in categories of study population (P = 0.01), but not in study type (P = 0.39) or sex (P = 0.33).

Conclusions: Diabetes mellitus 'probably' increases the risk of liver cancer among the Japanese population.

Citing Articles

Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data.

Guo Q, Zhu X, Beeraka N, Zhao R, Li S, Li F Sci Rep. 2024; 14(1):28131.

PMID: 39548154 PMC: 11568312. DOI: 10.1038/s41598-024-77658-2.


Risk-stratified hepatocellular carcinoma screening according to the degree of obesity and progression to cirrhosis for diabetic patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan: a cost-effectiveness study.

Kowada A BMJ Open. 2024; 14(11):e080549.

PMID: 39500609 PMC: 11552604. DOI: 10.1136/bmjopen-2023-080549.


Estrogen receptor 1 inhibits the progression of hepatocellular carcinoma via positively regulating lncRNA maternally expressed gene 3 under high glucose conditions.

Cheng T, Bai Y, Huang S, Wang Y, Zhou S, Liu H J Gastrointest Oncol. 2022; 13(5):2485-2496.

PMID: 36388662 PMC: 9660067. DOI: 10.21037/jgo-22-825.


Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer.

Kushchayeva Y, Kushchayev S, Jensen K, Brown R Cancers (Basel). 2022; 14(3).

PMID: 35158824 PMC: 8833385. DOI: 10.3390/cancers14030555.


Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan.

Hsu W, Sue S, Liang H, Tseng C, Lin H, Wen W Front Public Health. 2021; 9:711723.

PMID: 34604157 PMC: 8484707. DOI: 10.3389/fpubh.2021.711723.